A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease.
The mosquito-borne disease dengue (DEN) is caused by four serologically and genetically related viruses, termed DENV-1 to DENV-4. Infection with one DENV usually leads to acute illness and results in lifelong homotypic immunity, but individuals remain susceptible to infection by the other three DENVs. The lack of a small-animal model that mimics systemic DEN disease without neurovirulence has been an obstacle, but DENV-2 models that resemble human disease have been recently developed in AG129 mice (deficient in interferon alpha/beta and interferon gamma receptor signaling). However, comparable DENV-1, -3, and -4 models have not been developed. We utilized a non-mouse-adapted DENV-3 Thai human isolate to develop a lethal infection model in AG129 mice. Intraperitoneal inoculation of six to eight-week-old animals with strain C0360/94 led to rapid, fatal disease. Lethal C0360/94 infection resulted in physical signs of illness, high viral loads in the spleen, liver, and large intestine, histological changes in the liver and spleen tissues, and increased serum cytokine levels. Importantly, the animals developed vascular leakage, thrombocytopenia, and leukopenia. Overall, we have developed a lethal DENV-3 murine infection model, with no evidence of neurotropic disease based on a non-mouse-adapted human isolate, which can be used to investigate DEN pathogenesis and to evaluate candidate vaccines and antivirals. This suggests that murine models utilizing non-mouse-adapted isolates can be obtained for all four DENVs.


OBJECTIVE
Dengue (DEN) is a mosquito-borne disease caused by four DENV serotypes (DENV-1, -2, -3, and -4) that have no treatments or vaccines. Primary infection with one DENV usually leads to acute illness followed by lifelong homotypic immunity, but susceptibility to infection by the other three DENVs remains. Therefore, a vaccine needs to protect from all four DENVs simultaneously. To date a suitable animal model to mimic systemic human illness exists only for DENV-2 in immunocompromised mice using passaged viruses; however, models are still needed for the remaining serotypes. This study describes establishment of a lethal systemic DENV-3 infection model with a human isolate in immunocompromised mice and is the first report of lethal infection by a nonadapted clinical DENV isolate without evidence of neurological disease. Our DENV-3 model provides a relevant platform to test DEN vaccines and antivirals.
Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Vanessa V
VV
Sarathy
Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA.
Mellodee
M
White
Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Li
L
Li
Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA.
Summer R
SR
Gorder
Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Richard B
RB
Pyles
Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Gerald A
GA
Campbell
Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Gregg N
GN
Milligan
Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA nibourne@utmb.edu abarrett@utmb.edu.
Nigel
N
Bourne
Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA Center for Tropical Diseases, University of Texas Medical Branch, Galveston, Texas, USA Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, Texas, USA nibourne@utmb.edu abarrett@utmb.edu.
Alan D T
AD
Barrett
D000825:Animal Structures / Q000473:pathology / Q000821:virology; D000818:Animals; D003715:Dengue / Q000276:immunology / Q000473:pathology* / Q000821:virology*; D003716:Dengue Virus / Q000254:growth & development* / Q000276:immunology; D004195:Disease Models, Animal; D018345:Mice, Knockout; D017471:Receptors, Interferon / Q000172:deficiency; D016019:Survival Analysis
D017471:Receptors, Interferon